Regulatory Edge EyeStat is FDA-cleared and delivers objective blink-reflex data in minutes, positioning it well for adoption in trauma centers, emergency departments, and neurology clinics that require fast, reliable CNS diagnostics. Target buyers include hospital networks and rehab facilities seeking standardized metrics for TBI and differential diagnoses.

Growth Momentum The recent Series C raise of 6.23 million signals strong investor validation and growth potential, suggesting readiness to scale sales efforts and establish partnerships with larger hospital systems and CNS-focused distributors. Use this momentum to approach system integrators and regional health networks seeking innovative diagnostic tools.

Neurology Pipeline Beyond TBI, EyeStat's exploration into Parkinson's, Alzheimer's, and migraine creates multi-disease sales opportunities with neurology clinics, research centers, and pharma partners for diagnosis, monitoring, and clinical trials. Consider co-development or bundled offerings with CNS specialists to broaden adoption.

Partner Enablement As a small team, Blinktbi can maximize revenue through channel partnerships, CROs, and technology integrators, leveraging the sister CNS-focused program blinkcns for co-marketing and joint development. Build strategic alliances with hospital distributors and tele-neurology platforms to accelerate deployment.

Data Integration EyeStat's data-rich output is compatible with digital health ecosystems; opportunities exist to integrate with EMR/EHR systems, analytics dashboards, and clinical workflows to enable seamless adoption and measuring outcomes in TBI and CNS disorders. Propose pilot programs with health systems to demonstrate ROI and outcome improvements.